Truist Financial Corp Sells 48,650 Shares of Zoetis Inc. $ZTS

Truist Financial Corp decreased its position in Zoetis Inc. (NYSE:ZTS) by 37.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,144 shares of the company’s stock after selling 48,650 shares during the period. Truist Financial Corp’s holdings in Zoetis were worth $10,084,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Global Wealth Strategies & Associates bought a new position in Zoetis in the fourth quarter valued at about $25,000. Lodestone Wealth Management LLC bought a new position in Zoetis in the fourth quarter valued at about $30,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis in the third quarter valued at about $31,000. Holos Integrated Wealth LLC bought a new position in Zoetis in the fourth quarter valued at about $32,000. Finally, Board of the Pension Protection Fund bought a new position in Zoetis in the fourth quarter valued at about $38,000. Institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on ZTS shares. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. UBS Group cut their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research note on Friday. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Bank of America increased their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Finally, Citigroup initiated coverage on Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus target price of $141.25.

Zoetis Trading Down 5.2%

NYSE:ZTS opened at $82.80 on Friday. Zoetis Inc. has a 1-year low of $81.10 and a 1-year high of $172.23. The business’s 50-day moving average price is $118.49 and its two-hundred day moving average price is $123.70. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm has a market capitalization of $34.83 billion, a price-to-earnings ratio of 13.73, a PEG ratio of 1.34 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 61.97%. The company had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the company posted $1.48 EPS. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts expect that Zoetis Inc. will post 7.01 earnings per share for the current year.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: JPMorgan lowered its price target on Zoetis from $190 to $130, but kept an overweight rating, implying the stock still has meaningful upside from current levels. Benzinga report on JPMorgan target cut
• Neutral Sentiment: Some analysts remain constructive overall, with recent coverage still showing buy/overweight views and price targets well above the current share price, suggesting longer-term confidence despite near-term pressure.
• Negative Sentiment: Zoetis missed Q1 earnings and revenue estimates, which immediately hurt sentiment around the stock.
• Negative Sentiment: The company cut its FY2026 guidance after seeing weaker U.S. companion animal demand and pricing pressure, raising concerns that pet owners are spending less on veterinary care and premium products. Benzinga report on weak pet care demand
• Negative Sentiment: Media coverage described the earnings release as a sharp disappointment, with reports highlighting a steep selloff after investors reacted to the softer outlook.
• Negative Sentiment: Ademi LLP announced a securities fraud investigation into Zoetis, adding another overhang for shares as investors assess potential legal risk.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.